The transition from product launch to long-term market presence requires a shift in focus toward rigorous surveillance and complaint management. Manufacturers must ensure their quality management systems remain robust enough to identify emerging safety signals and distinguish between isolated incidents and reportable events. This session offers a framework for maintaining inspection readiness, moving beyond reactive measures to address underlying system deficiencies before they escalate into formal regulatory challenges.

Participants will examine strategies for handling FDA Form 483 observations and Warning Letters. The discussion centers on drafting precise, timely responses that satisfy regulators while simultaneously hardening internal processes against future non-compliance risks. By aligning quality and regulatory workflows, companies can better protect device availability and maintain market standing.